1.42
+0.02(+1.43%)
Currency In USD
| Previous Close | 1.4 |
| Open | 1.38 |
| Day High | 1.45 |
| Day Low | 1.38 |
| 52-Week High | 2.06 |
| 52-Week Low | 1.13 |
| Volume | 91,041 |
| Average Volume | 1.02M |
| Market Cap | 69.64M |
| PE | -5.68 |
| EPS | -0.25 |
| Moving Average 50 Days | 1.43 |
| Moving Average 200 Days | 1.36 |
| Change | 0.02 |
If you invested $1000 in MediciNova, Inc. (MNOV) 10 years ago, it would be worth $361.32 as of January 09, 2026 at a share price of $1.42. Whereas If you bought $1000 worth of MediciNova, Inc. (MNOV) shares 5 years ago, it would be worth $254.94 as of January 09, 2026 at a share price of $1.42.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
2026 New Year’s Greetings from the CEO
GlobeNewswire Inc.
Jan 06, 2026 2:00 PM GMT
LA JOLLA, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) provides shareholders a corpo
MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy
GlobeNewswire Inc.
Dec 18, 2025 11:00 AM GMT
LA JOLLA, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the successf
MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND
GlobeNewswire Inc.
Dec 08, 2025 11:00 AM GMT
LA JOLLA, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company listed on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code: 4875), today announced an update and the